[Effects of angiotensin II analogue (1-sarcosine, 8-isoleucine-angiotensin II) in various types of hypertension]. 1975

M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
June 1974, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
April 1973, The Journal of pharmacology and experimental therapeutics,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
May 1978, Clinical pharmacology and therapeutics,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
March 1987, Revista espanola de fisiologia,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
January 1976, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
April 1990, Nihon Kyobu Shikkan Gakkai zasshi,
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
January 1984, Quarterly journal of experimental physiology (Cambridge, England),
M Yasujima, and K Abe, and H Aoyagi, and N Irokawa, and H Memezawa
January 1983, The Journal of urology,
Copied contents to your clipboard!